Significant Ownership of Sands Capital Life Sciences Pulse Fund II, L.P.

Signature - Title
/s/ Jonathan Goodman - Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund II, L.P.
Location
Arlington, VA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Sands Capital Life Sciences Pulse Fund II, L.P..

Notify me when Sands Capital Life Sciences Pulse Fund II, L.P. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Sands Capital Life Sciences Pulse Fund II, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
IKT Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share 11% $26,037,930 +$4,137,930 13,018,965 +19% Sands Capital Life Sciences Pulse Fund II, L.P. 31 Dec 2025
BBNX Beta Bionics, Inc. Common Stock 8.2% $48,410,732 +$5,636,946 3,570,113 +13% Sands Capital Life Sciences Pulse Fund II. L.P. 30 Jun 2025
ACRV Acrivon Therapeutics, Inc. Common Stock, par value $0.001 per share 6.8% $2,525,900 2,122,605 Sands Capital Life Sciences Pulse Fund II, L.P. 30 Jun 2025

Schedules 13D/G Reported by Sands Capital Life Sciences Pulse Fund II, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.